Although BRAF is a driver mutation in several tumor types, and BRAF inhibitors have clinical activity in BRAF V600E–mutated non–small cell lung cancer (NSCLC) and melanoma, previous studies have shown that anti-BRAF inhibitor monotherapy has a response rate of only 5% in previously treated BRAF V600E-mutated CRC [2, 7, 8]. This evidence concerns the gene BRAF and melanoma.